Effect of human immunodeficiency virus type 1 infection on the antibody response to a glycoprotein conjugate pneumococcal vaccine: Results from a randomized trial

Journal of Infectious Diseases

Volumn 173, Issue 1, 1996, Pages 83-90

  Ahmed, Faruque ^b   Steinhoff, Mark C ^a   Rodriguez Barradas, Maria C ^b   Hamilton, Robert G ^b   Musher, Daniel M ^b   Nelson, Kenrad E ^b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; IMMUNOGLOBULIN G ANTIBODY; PNEUMOCOCCUS GLYCOPROTEIN CONJUGATE VACCINE; PNEUMOCOCCUS VACCINE; POLYSACCHARIDE VACCINE; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BACTEREMIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG FORMULATION; DRUG MECHANISM; ERYTHEMA; FEMALE; FEVER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGENICITY; INJECTION PAIN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE;

EID: 0030065415     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/173.1.83     Document Type: Article

References (16)

1. Centers for Disease Control. Pneumococcal polysaccharide vaccine. MMWR 1989;38:64-76.
2. Polsky B, Gold JWM, Whimbey E, et al. Bacterial pneumonia in patients with acquired immunodeficiency syndrome. Ann Intern Med 1986;104:38-41.
3. Schuchat A, Broome CV, Hightower A, Costa SJ, Parkin W. Use of surveillance for invasive pneumococcal disease to estimate the size of the immunosuppressed HIV-infected population. JAMA 1991; 265:3275-9.
4. Selwyn PA, Feingold AR, Hartel D, et al. Increased risk of bacterial pneumonia in HIV-infected intravenous drug users with AIDS. AIDS 1988;2:267-72.
5. Witt DJ, Craven DE, McCabe WR. Bacterial infections in adult patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. Am J Med 1987;82:900-6.
6. Simberkoff MS, El Sadr W, Schiffman G, Raha JJ. Streptococcus pneumoniae infections and bacteremia in patients with acquired immunodeficiency syndrome, with report of pneumococcal vaccine failure. Am Rev Respir Dis 1984;130:1174-6.
7. Redd SC, Rutherford GW, Sande MA, et al. The role of human immunodeficiency virus infection in pneumococcal bacteremia in San Francisco residents. J Infect Dis 1990;162:1012-7.
8. Pesola GR, Charles A. Pneumococcal bacteremia with pneumonia. Mortality in acquired immunodeficiency syndrome. Chest 1992;101:150-5.
9. Fiebach N, Beckett W. Prevention of respiratory infections in adults: influenza and pneumococcal vaccines. Arch Intern Med 1994;154: 2545-57.
10. Shapiro ED, Berg AT, Austrian R, et al. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N Engl J Med 1991; 325:1453-60.
11. Broome CV, Facklam RR, Fraser DW. Pneumococcal disease after pneumococcal vaccination: an alternative method to estimate the efficacy of pneumococcal vaccine. N Engl J Med 1980;303;549-52.
12. Janoff EN, Douglas JM, Gabriel M, et al. Class-specific antibody responses to pneumococcal capsular polysaccharides in men infected with human immunodeficiency virus type 1. J Infect Dis 1988;158:983-90.
13. Pinching AJ. Antibody responses in HIV infection. Clin Exp Immunol 1991;84:181-4.
14. McIntyre P. Vaccines against invasive Haemophilus influenzae type b disease. J Paediatr Child Health 1994;30:14-8.
15. Glaser JB, Volpe S, Aguirre A, Simpkins H, Schiffman G. Zidovudine improves response to pneumococcal vaccine among persons with AIDS and AIDS-related complex. J Infect Dis 1991;164:761-4.
16. Dintzis RZ. Rational design of conjugate vaccines. Pediatr Res 1992;32:376-85.